FR2591894B1 - Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques - Google Patents

Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques

Info

Publication number
FR2591894B1
FR2591894B1 FR8518981A FR8518981A FR2591894B1 FR 2591894 B1 FR2591894 B1 FR 2591894B1 FR 8518981 A FR8518981 A FR 8518981A FR 8518981 A FR8518981 A FR 8518981A FR 2591894 B1 FR2591894 B1 FR 2591894B1
Authority
FR
France
Prior art keywords
immunotoxins
polysaccharide
lasting
vivo
patterns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8518981A
Other languages
English (en)
Other versions
FR2591894A1 (fr
Inventor
Pierre Casellas
Bernard Bourrie
Xavier Canat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR8518981A priority Critical patent/FR2591894B1/fr
Priority to US06/941,990 priority patent/US4911911A/en
Priority to IL80972A priority patent/IL80972A/xx
Priority to ES86402812T priority patent/ES2020945B3/es
Priority to AT86402812T priority patent/ATE59049T1/de
Priority to EP86402812A priority patent/EP0234151B1/fr
Priority to DE8686402812T priority patent/DE3676187D1/de
Priority to AU66630/86A priority patent/AU602320B2/en
Priority to PT83946A priority patent/PT83946B/pt
Priority to CA000525646A priority patent/CA1276108C/fr
Priority to NZ218705A priority patent/NZ218705A/xx
Priority to IE330586A priority patent/IE59649B1/en
Priority to DK611886A priority patent/DK611886A/da
Priority to ZA869572A priority patent/ZA869572B/xx
Priority to AR86306243A priority patent/AR242958A1/es
Priority to JP61302889A priority patent/JPH0742316B2/ja
Priority to KR1019860011019A priority patent/KR950007215B1/ko
Publication of FR2591894A1 publication Critical patent/FR2591894A1/fr
Application granted granted Critical
Publication of FR2591894B1 publication Critical patent/FR2591894B1/fr
Priority to US07/404,052 priority patent/US5104976A/en
Priority to GR91400316T priority patent/GR3001597T3/el
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR8518981A 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques Expired FR2591894B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR8518981A FR2591894B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
US06/941,990 US4911911A (en) 1985-12-20 1986-12-15 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
IL80972A IL80972A (en) 1985-12-20 1986-12-15 Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
ES86402812T ES2020945B3 (es) 1985-12-20 1986-12-16 Glicoproteinas modificadas por oxidacion y formacion de bases de schiff, que inhiben los ribosomas, procedimiento de obtencion e inmunotoxinas que comprenden una glicoproteina como esta.
AT86402812T ATE59049T1 (de) 1985-12-20 1986-12-16 Die ribosome inhibierende, mittels oxidation und bildung von schiffbasen modifizierte glukoproteine, verfahren zur herstellung derselben und ein solches glukoprotein enthaltende immunotoxine.
EP86402812A EP0234151B1 (fr) 1985-12-20 1986-12-16 Glycoprotéines modifiées par oxydation et formation de base de Schiff, inhibant les ribosomes, procédé d'obtention et immunotoxines comprenant une telle glycoprotéine
DE8686402812T DE3676187D1 (de) 1985-12-20 1986-12-16 Die ribosome inhibierende, mittels oxidation und bildung von schiffbasen modifizierte glukoproteine, verfahren zur herstellung derselben und ein solches glukoprotein enthaltende immunotoxine.
PT83946A PT83946B (pt) 1985-12-20 1986-12-17 Processo para a obtencao de glicoproteinas inibidoras dos ribosomas, modificadas por oxidacao das funcoes osidicas e formacao de uma base de schiff
CA000525646A CA1276108C (fr) 1985-12-20 1986-12-17 Procede de modification des glycoproteines inactivant les ribosomes par oxydation des groupements oside et formation d'une base de schiff
AU66630/86A AU602320B2 (en) 1985-12-20 1986-12-17 Ribosome inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged-action immunotoxins containing such a glycoprotein
NZ218705A NZ218705A (en) 1985-12-20 1986-12-18 Glycoproteins with ribosome-inhibiting properties and immunotoxins
IE330586A IE59649B1 (en) 1985-12-20 1986-12-18 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and invivo prolonged-action immunotoxins containing such a glycoprotein
DK611886A DK611886A (da) 1985-12-20 1986-12-18 Riboson-inaktiverende glycoproteiner og immunotoksiner med forlaengetvirkning in vivo, der indeholder et saadant glycoprotein
ZA869572A ZA869572B (en) 1985-12-20 1986-12-19 Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged-action immunotoxins containing such a glycoprotein
AR86306243A AR242958A1 (es) 1985-12-20 1986-12-19 Un procedimiento para la obtencion de un gpir modificada, y procedimiento para obtener una inmunotoxina utilizando dicho gpir modificada.
JP61302889A JPH0742316B2 (ja) 1985-12-20 1986-12-20 オシド単位の酸化およびシツフ塩基の形成により変性されたリボソ−ム不活性化糖タンパク、およびこの糖タンパクを含む生体内持続性免疫毒素
KR1019860011019A KR950007215B1 (ko) 1985-12-20 1986-12-20 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
US07/404,052 US5104976A (en) 1985-12-20 1989-09-08 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
GR91400316T GR3001597T3 (en) 1985-12-20 1991-03-12 Glycoproteins modified by oxidation and formation of schiff bases, inhibiting ribosomes, process for obtaining the same, and immunotoxines containing such glycoprotein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8518981A FR2591894B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques

Publications (2)

Publication Number Publication Date
FR2591894A1 FR2591894A1 (fr) 1987-06-26
FR2591894B1 true FR2591894B1 (fr) 1988-04-01

Family

ID=9326038

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8518981A Expired FR2591894B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques

Country Status (2)

Country Link
FR (1) FR2591894B1 (fr)
ZA (1) ZA869572B (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps

Also Published As

Publication number Publication date
FR2591894A1 (fr) 1987-06-26
ZA869572B (en) 1987-08-26

Similar Documents

Publication Publication Date Title
NO307835B1 (no) Ikke-farmasøytisk polysakkaridkonjugat
DE68927097D1 (de) Differentieller refraktometer
FI905579A0 (fi) Modem med flera arbetssaett.
DE68928739D1 (de) Detecteur d'humidite
MX164779B (es) Mejoras a ductos de poliepoxido-polioxalquilenpoliamina glicidol modificados
DK0734212T3 (da) Kontaktflade med naturligt aftryk
DE68927610D1 (de) Antikörper-Arzneimittel Konjugale
DK186190D0 (da) Samlbaandet gmsk-modem
EP0383868A4 (en) 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
MX164394B (es) Llavero
FR2591895B1 (fr) Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
MX164816B (es) Composicion y metodo para producir 1,3,5-trinitro-2,4,6-tripicrilbenceno
IT8822249A0 (it) Perfezionamenti apportati a borse e prodotti similari.
FR2591894B1 (fr) Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
PT91615A (pt) Ensemble d'allaitement
IT1240753B (it) Albero a camme e metodo per produrlo.
KR900700425A (ko) 2,3-디플루오로페놀 유도체
FR2646221B1 (fr) Joint d'etancheite, dispositif le comportant et application a une turbomachine
KR920003449B1 (en) Tripple rail logic gate
IT1183667B (it) Catena ad aghi e a griffa
ZA876594B (en) Triblock polymer and synthesis technique
FR2628333B1 (fr) Engin de glisse sur neige
FR2567164B1 (fr) Machine de detorsion et d'ouverture des tricots.
IT1245851B (it) 13-desosso-4'-desossi-4'-iodoantracicline
FR2579710B1 (fr) Chaine constituee de maillons munis chacun d'un couple de colliers

Legal Events

Date Code Title Description
ST Notification of lapse